SSRIs explained

What SSRIs are

SSRIs, selective serotonin reuptake inhibitors, are the most commonly prescribed class of antidepressants. The name points to depression, but it understates what they do. SSRIs are first-line for most anxiety disorders, and they are also used for obsessive-compulsive disorder, post-traumatic stress disorder, and premenstrual dysphoric disorder.

The "selective" part of the name is worth a moment. It means these medications act mainly on serotonin and leave most other systems alone. That selectivity is the reason they are easier to tolerate, and far safer in overdose, than the older antidepressants they replaced.

The main SSRIs are sertraline (Zoloft), escitalopram (Lexapro), fluoxetine (Prozac), citalopram (Celexa), paroxetine (Paxil), and fluvoxamine (Luvox).

How they work

Serotonin is a chemical messenger that nerve cells use to pass signals to one another. One cell releases serotonin into the small gap between cells, the next cell picks up the signal, and then the releasing cell reabsorbs much of the serotonin it sent out. That reabsorption is called reuptake. SSRIs slow reuptake, so serotonin stays in that gap longer and more of it is available between cells.

It is worth being honest about the limits of this explanation. The popular "chemical imbalance" idea, the notion that depression is simply too little serotonin and an SSRI tops it up, is an oversimplification. The full picture of how SSRIs ease depression and anxiety is not known. The change in serotonin levels happens within hours of the first dose, but people do not feel better within hours. That gap is a clue. The early change in serotonin signaling seems to set off slower adjustments in the brain over the following weeks, changes in how nerve cells respond and connect. Those slower changes are thought to do the real work. That is why SSRIs take time to help rather than working the day you start them.

How the class developed

SSRIs were designed to be more selective, and much safer, than the antidepressants that came before them. Those older drugs, the tricyclic antidepressants and the MAOIs, worked, but they acted on many systems at once. That made them hard to tolerate, and dangerous in overdose, which is a serious concern in people being treated for depression.

Fluoxetine, sold as Prozac, was the first SSRI to reach wide use. It came to the U.S. market in the late 1980s, and other SSRIs followed through the 1990s. SSRIs became first-line treatment, but not because they outperform the older drugs on effectiveness. On that measure they are broadly comparable. They became first-line because they are far safer in overdose and much better tolerated, so more people can stay on them long enough to benefit.

What they treat

SSRIs treat a wider range of conditions than the name suggests. Across the class, they are used for major depressive disorder, generalized anxiety disorder, panic disorder, social anxiety disorder, obsessive-compulsive disorder, post-traumatic stress disorder, and premenstrual dysphoric disorder.

No single SSRI is approved for every one of these. Each medication carries its own set of FDA-approved uses, and prescribers also use them off-label, meaning for a purpose the label doesn't formally list even though evidence and practice support it. Sertraline and paroxetine carry some of the broadest approvals. Fluvoxamine is used in particular for OCD. The practical point is that a single class of medication covers depression and most anxiety disorders, which is useful, because those conditions often appear together in the same person.

What the SSRIs have in common

The medications in this class share a lot.

• A timeline of four to six weeks for the fuller effect, sometimes up to eight.
• Early side effects that tend to arrive before the benefits.
• A shared set of common side effects: stomach effects such as nausea and looser stools, changes in sleep, increased sweating, and sexual side effects.
• Discontinuation symptoms if stopped abruptly, so they need a gradual taper planned with a prescriber.
• The antidepressant boxed warning about a possible increase in suicidal thoughts in people under 25, especially early in treatment.
• A small risk of serotonin syndrome, a reaction caused by too much serotonin activity, especially when an SSRI is combined with other serotonergic drugs.
• A slightly raised risk of bleeding and bruising, which adds up with NSAIDs, aspirin, or blood thinners.

SSRIs are not addictive in the usual sense. They do not cause cravings or compulsive use, and people do not need ever-higher doses to get the same effect. The body does adjust to them, which is why stopping should be gradual. Adjustment and addiction are not the same thing.

How they differ from each other

The SSRIs are not interchangeable. A few real differences shape the choice.

Half-life. Half-life is how long the drug takes to clear from the body. Fluoxetine has by far the longest half-life of the group, so its active form lingers for weeks after the last dose. Paroxetine is among the shortest-acting. This matters most when stopping. A longer half-life means the drug tapers itself, so fluoxetine is gentler to come off. A shorter half-life means the level drops quickly between doses, which is why paroxetine is the SSRI best known for discontinuation symptoms.

Activation versus sedation. Fluoxetine tends to be more activating, so it can bring early jitteriness and is usually taken in the morning. Paroxetine tends to be more sedating, which can suit someone who is keyed up or sleeping poorly, and it is often taken in the evening.

Heart rhythm. Citalopram and escitalopram have a dose-related effect on the QT interval, a measure of the heart's electrical cycle. Because of this, citalopram and escitalopram have dose ceilings, and those ceilings are lower in older adults and in people with liver problems.

Drug interactions. Fluoxetine and paroxetine affect liver enzymes that break down many other medications, so they change the levels of more drugs than sertraline or escitalopram do. For someone taking several medications, that heavier interaction profile can steer the choice.

Weight. SSRIs are fairly weight-neutral as a group, but paroxetine has a greater tendency toward weight gain over months of use than the others.

How a prescriber chooses one

A prescriber weighs several things. Prior response in the person, or sometimes in a close relative, is a strong guide. So is the side-effect profile that fits a given person best. An activating SSRI may suit someone with low energy, while a calming one may suit someone who feels agitated. Other medications matter, since fluoxetine and paroxetine interact with more drugs. Health conditions matter too, which is why the QT effect can steer a prescriber away from citalopram or escitalopram for some people. And the diagnosis matters, since the SSRIs differ in their approved uses.

An honest point is worth making here. No single SSRI is dramatically better than the others on effectiveness. Finding the right fit can take a try or two. That is a normal part of treatment rather than a sign that the approach is wrong.

The medications in this class

• Sertraline (Zoloft). A widely used SSRI with a broad set of approved uses across depression and several anxiety-related conditions.
• Escitalopram (Lexapro). An SSRI with simple dosing and a very low interaction profile, often regarded as well tolerated.
• Fluoxetine (Prozac). One of the oldest SSRIs, more activating than most, with a long half-life that makes it gentler to stop.
• Citalopram (Celexa). An SSRI used mainly for depression, with a dose-related effect on heart rhythm that shapes its maximum dose.
• Paroxetine (Paxil). A more sedating SSRI that is shorter-acting, more linked to weight gain, and best known for discontinuation symptoms.
• Fluvoxamine (Luvox). An SSRI used in particular for obsessive-compulsive disorder.

PsychiatryRx has a dedicated guide for several of these medications, with more detail on uses, side effects, dosing, and what to expect.

Common questions

How long do SSRIs take to work? Some early effects on sleep and appetite can show within one to two weeks. The fuller effect on mood and anxiety usually takes four to six weeks, sometimes up to eight. Side effects often arrive before the benefit, so the first weeks can feel discouraging even when the medication is working.

Are SSRIs addictive? No, not in the usual sense. They do not cause cravings or compulsive use, and people do not need rising doses to keep the effect. The body does adjust to them, which is why stopping should be gradual and planned with a prescriber. That is dependence in the mild physical sense, not addiction.

Is one SSRI better than another? Not really, on effectiveness. The SSRIs are broadly similar in how well they work. They differ in half-life, in activation versus sedation, in drug interactions, and in specific approved uses. The right one is the one that fits a given person, and finding it can take a try or two.

Is it safe to take an SSRI long-term? For many people, yes. SSRIs are among the most studied medications in psychiatry, and long-term use is common and well established. Whether to continue depends on the condition, how many episodes a person has had, and how things are going. That is a decision to revisit with a prescriber over time, not a fixed end date.

Sources

This guide draws on current prescribing information and public health references. It is reviewed for clinical accuracy and updated as guidance changes.

1. U.S. Food and Drug Administration. Prescribing information.
2. MedlinePlus, U.S. National Library of Medicine.
3. National Institute of Mental Health. Mental health medications.
4. American Psychiatric Association. Practice guideline for the treatment of patients with major depressive disorder.